Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment SolutionGlobeNewsWire • 08/11/22
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for HypertensionAccesswire • 08/10/22
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse EventsAccesswire • 07/27/22
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in JapanAccesswire • 07/26/22
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese MarketAccesswire • 06/03/22
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech SpaceGlobeNewsWire • 05/26/22
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine SpaceGlobeNewsWire • 05/25/22
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive ResultsAccesswire • 04/14/22